CKAP5 and Miyoshi myopathy: Treatment with αCD38‐tLNPs‐siRNA‐CKAP5 caused a significant reduction in the occupancy of MM cells in the BM and spleen, and decreased the overall disease burden, as indicated by the lower levels of monoclonal protein in the serum.